Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MANKIND.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MANKIND.BO and 80,000+ other tickers.
See exactly how MANKIND.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MANKIND.BO and 80,000+ other tickers.
Headquartered in New Delhi, India, Mankind Pharma Limited is a prominent developer, manufacturer, and marketer of pharmaceutical formulations and consumer healthcare products. The company's primary focus is on the Indian market, though it also boasts an international reach. Its extensive pharmaceutical portfolio addresses a broad spectrum of acute and chronic therapeutic areas, encompassing anti-infectives, cardiovascular and gastrointestinal health, anti-diabetic treatments, dermatology, pain management, neurological and CNS disorders, vitamin/mineral/nutrient supplements, and respiratory…
No recent news available.